UChicago study finds lasofoxifene a promising treatment for resistant breast cancer

Source : https://www.eurekalert.org/pub_releases/2021-05/uocm-usf051321.php

In a study carried out in mice at the University of Chicago, researchers found that lasofoxifene outperformed fulvestrant, the current gold-standard drug, in reducing or preventing primary tumor growth. It also was more effective at preventing metastasis in the lung, liver, bone and brain, the four most common areas for this cancer to spread.